Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 48)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Glucagon |
Approved |
Phase 2 |
|
16941-32-5 |
16133228 16186314 |
Synonyms:
[<sup>125</sup>I]-glucagon
GCG(53-81)
GLUCAGEN HYPOKIT
GLUCAGON
Glucagon (recombinant dna origin)
GLUCAGON EMERGENCY KIT
|
GLUCAGON RECOMBINANT
Glucagon, human
Glucagon, porcine
GLUCAGONE
GLUCAGONUM
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
|
|
2 |
|
Dulaglutide |
Approved, Investigational |
Phase 2 |
|
923950-08-7 |
|
Synonyms:
Dulaglutida
DULAGLUTIDE
LY2189265
|
|
|
3 |
|
Esomeprazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
73590-58-6, 119141-88-7 |
9568614 4594 |
Synonyms:
( -)-Omeprazole
(−)-omeprazole
(-)-Omeprazole
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(S)-Omeprazole
(S)-omeprazole|Nexium®
2,3,5-Trimethylpyridine/Omeprazole
A02BC05
Alenia
Antra
Antra mups
AstraZeneca brand OF esomeprazole magnesium
Audazol
Aulcer
Axagon
Belmazol
Ceprandal
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
EMOZUL
Epirazole
Erbolin
Escz
Esofag
Esomeprazol
Esomeprazole
Ésoméprazole
Esomeprazole magnesium
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168/68|Losec®|Prilosec®
H-168/68
Indurgan
Inexium paranova
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
LOSEC MUPS
Lucen
Magnesium, omeprazole
Mepral
MEZZOPRAM
Miol
Miracid
Mopral
Morecon
Nexiam
Nexium
NEXIUM CONTROL
NEXIUM I.V.
Nexium IV
Nilsec
Nopramin
|
Nuclosina
Ocid
Olexin
Omapren
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole magnesium
Omeprazole pellets
Omeprazole S-form
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprol
OMERAN
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prilosec
Prilosec otc
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
Sanamidol
Secrepina
Sodium, omeprazole
Strontium, esomeprazole
Tedec ulceral
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
VENTRA
Victrix
ZANPROL
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
4 |
|
Lecithin |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
8002-43-5, 1446756-47-3, 18656-38-7 |
26197 9547096 6323481 |
Synonyms:
(1)-(7-Myristoyl-4-oxido-10-oxo-3,5,9-trioxa-4-phosphatricosyl)trimethylammonium 4-oxide
(2S)-2-Amino-3-({[(2R)-2-(butanoyloxy)-3-(propanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoate
[2-({[2,3-bis(tetradecanoyloxy)propyl] phosphonato}oxy)ethyl]trimethylazanium
1,2 Dimyristoyl glycero 3 phosphorylcholine
1,2 Ditetradecanoyl glycero 3 phosphocholine
1,2 Ditetradecyl glycero 3 phosphocholine
1,2-Dimyristoyl-glycero-3-phosphorylcholine
1,2-Dimyristoyl-sn-glycero-3-phosphatidylcholine
1,2-Dioctadecanoyl-rac-glycero-3-phosphoserine
1,2-Dioctadecanoyl-sn-glycero-3-phosphoserine
1,2-Distearoyl-rac-glycero-3-phosphoserine
1,2-Ditetradecanoyl-glycero-3-phosphocholine
1,2-Ditetradecanoyl-sn-glycero-3-phosphocholine
1,2-Ditetradecyl-glycero-3-phosphocholine
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2,3-Bis(tetradecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
2,3-Bis(tetradecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphoric acid
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
3-O-sn-Phosphatidyl-L-serine
Acetylglucosamine
D-GlcNAc
dimyristoyl phosphatidylcholine
Dimyristoyllecithin
|
Dimyristoylphosphatidylcholine
Dimyristoyl-phosphatidylcholine
Distearoyl phosphatidylserine
distearoylphosphatidylserine|PS
DMCP
DMPC
Lecithins
l-α-dimyristoylphosphatidylcholine
N Acetyl D glucosamine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
O3-Phosphatidyl-L-serine
Phosphatidyl serine
Phosphatidylcholine
Phosphatidyl-L-serine
Phosphatidylserine
Phosphatidylserine(18:0/18:0)
Phosphatidylserine(36:0)
Phospholutein
PS
PS(18:0/18:0)
PS(36:0)
pSer(18:0/18:0)
pSer(36:0)
|
|
5 |
|
Choline |
Approved, Nutraceutical |
Phase 2 |
|
62-49-7 |
305 |
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(2-HYDROXYETHYL)TRIMETHYLAZANIUM
(beta-Hydroxyethyl)trimethylammonium
2-HYDROXYETHYL-TRIMETHYL-AMMONIUM
2-HYDROXYETHYL-TRIMETHYL-AZANIUM
2-Hydroxy-N,N,N-trimethylethanaminium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
Bilineurine
Biocolina
Biocoline
Bitartrate, choline
Bursine
Chloride, choline
CHOLINE
Choline bitartrate
Choline cation
Choline chloride
Choline citrate
Choline hydroxide
|
CHOLINE ion
Choline O sulfate
Choline O-sulfate
Cholinum
Citrate, choline
Fagine
Hepacholine
Hormocline
Hydroxide, choline
Lipotril
N,N,N-Trimethylethanolammonium
N,N,N-Trimethylethanol-ammonium
Neocolina
N-Trimethylethanolamine
O-Sulfate, choline
Paresan
Trimethylethanolamine
Vidine
Vitamin J
|
|
6 |
|
Bile Acids and Salts |
|
Phase 2 |
|
|
|
7 |
|
Omega 3 Fatty Acid |
|
Phase 2 |
|
|
|
8 |
|
Flax |
|
Phase 2 |
|
|
|
9 |
|
Soy Bean |
|
Phase 2 |
|
|
|
10 |
|
Sunflower |
|
Phase 2 |
|
|
|
11 |
|
Insulin, Globin Zinc |
|
Phase 2 |
|
|
|
12 |
|
Insulin |
|
Phase 2 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
13 |
|
Hypoglycemic Agents |
|
Phase 2 |
|
|
|
14 |
|
Glucagon-Like Peptide 1 |
|
Phase 2 |
|
|
|
15 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
16 |
|
Antacids |
|
Phase 2 |
|
|
|
17 |
|
Proton Pump Inhibitors |
|
Phase 2 |
|
|
|
18 |
|
Phylloquinone |
Approved, Investigational |
Phase 1 |
|
84-80-0 |
5284607 |
Synonyms:
(2S)-2-(Henicosanoyloxy)-3-(tridecanoyloxy)propyl (7Z,10Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
2',3'-trans-Vitamin K1
2’,3’-trans-vitamin K1
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
2-METHYL-3-[(2E)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL]-1,4-DIHYDRONAPHTHALENE-1,4-DIONE
2-METHYL-3-[(2E,7R,11R)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL]NAPHTHALENE-1,4-DIONE
2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
2-METHYL-3-PHYTHYL-1,4-NAPHTHOCHINON
2-Methyl-3-phytyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthoquinone
2-METHYL-3-PHYTYL-1,4-NAPTHOQUINONE
3-Phytylmenadione
alpha-Phylloquinone
ANTIHEMORRHAGIC VITAMIN
a-Phylloquinone
AQUA MEPHYTON
AQUA-MEPHYTIN
Aquamephyton
COMBINAL K1
Fitomenadiona
FITOMENADIONE
KANAVIT
KATIV N
KEPHTON
KINADION
K-JECT
|
Konakion
KONAKION MM
KONAKION MM PAED
MEPHYTON
MONODION
MONO-KAY
NEOKAY
NSC-270681
ORAKAY
Phyllochinon
Phyllochinonum
Phyllohydroquinone
Phylloquinone
PHYLLOQUINONE E-FORM
PHYTHYL-MENADION
Phytomenadione
Phytomenadionum
Phytonadione
Phytonadionum
Phytylmenadione
SYNTHEX P
trans-Phylloquinone
VITAMIN K
Vitamin K 1
Vitamin K hydroquinone (phylloquinone)
Vitamin K1
Α-phylloquinone
|
|
19 |
|
Menadione |
Approved, Nutraceutical |
Phase 1 |
|
58-27-5 |
4055 |
Synonyms:
2-METHYL-1,4-DIHYDRONAPHTHALENE-1,4-DIONE
2-Methyl-1,4-naftochinon
2-Methyl-1,4-naphthalendione
2-Methyl-1,4-naphthalenedione
2-Methyl-1,4-naphthochinon
2-Methyl-1,4-naphthodione
2-Methyl-1,4-naphthoquinone
2-Methylnaphthoquinone
3-Methyl-1,4-naphthoquinone
Aquakay
Aquinone
Bisulfite, menadione
Bisulfite, menadione sodium
Hemodal
Juva-K
Kaergona
Kanone
Kappaxan
Kappaxin
Karcon
Kareon
Kativ-g
Kayklot
Kaykot
Kaynone
Kayquinone
Kipca
Kipca-oil soluble
Klottone
Koaxin
Kolklot
|
K-Thrombyl
K-Vitan
Menadion
MENADIONE
Menadione bisulfite
Menadione sodium bisulfite
Menadione sodium bisulfite, trihydrate
Menaphthene
Menaphthon
Menaphthone
Menaphtone
Menaquinone
Menaquinone O
Mitenon
Mitenone
MNQ
NSC-4170
Panosine
Prokayvit
Sodium bisulfite, menadione
Synkay
Thyloquinone
Vicasol
Vikasol
Vitamin K 3
Vitamin K0
Vitamin K2
Vitamin K3
Vitamin K3 sodium bisulfite
Vitamin K3: 1,4-dihydro-1,4-dioxo-2-methylnaphthalene
|
|
20 |
|
Menaquinone |
Investigational |
Phase 1 |
|
1182-68-9 |
|
21 |
|
Vitamins |
|
Phase 1 |
|
|
|
22 |
|
Vitamin K |
|
Phase 1 |
|
|
|
23 |
|
Trace Elements |
|
Phase 1 |
|
|
|
24 |
|
Antifibrinolytic Agents |
|
Phase 1 |
|
|
|
25 |
|
Hemostatics |
|
Phase 1 |
|
|
|
26 |
|
Naphthoquinone |
|
Phase 1 |
|
|
|
Synonyms:
[1,4]Naphthoquinon
1,4-Dihydro-1,4-diketonaphthalene
1,4-Naphthalenedione
1,4-NAPHTHOQUINONE
1,4-NAPHTHO-QUINONE
1,4-NQ
alpha-Naphthoquinone
|
a-Naphthoquinone
NAPHTHALENE-1,4-DIONE
Naphthoquinone
NAPHTHOQUINONE 1
p-Naphthoquinone
Succivil
Α-naphthoquinone
|
|
27 |
|
Micronutrients |
|
Phase 1 |
|
|
|
28 |
|
Coagulants |
|
Phase 1 |
|
|
|
29 |
|
Carbamide peroxide |
Approved |
|
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
30 |
|
Repaglinide |
Approved, Investigational |
|
|
135062-02-1 |
65981 |
Synonyms:
(-)-REPAGLINIDE
(-)-repaglinide|AGEE-623ZW|Prandin®
2-Ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid
2-Ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
A10BX02
AG-ee 388
AG-ee 388 ZW
AG-ee 623 ZW
AGEE-623ZW
AG-EE-623ZW
AG-EE-623-ZW
ENYGLID
Glaxo wellcome brand OF replaginide
|
GlucoNorm
Novo nordisk brand 2 OF repaglinide
Novo nordisk brand OF repaglinide
NovoNorm
Prandin
REPAGLINIDA
Repaglinida [INN-Spanish]
Repa-glinide
REPAGLINIDE
Repaglinide, (+-)-isomer
REPAGLINIDUM
Repaglinidum [INN-Latin]
Surepost
|
|
31 |
|
Flurbiprofen |
Approved, Investigational |
|
|
5104-49-4 |
3394 |
Synonyms:
(+-)-2-Fluoro-alpha-methyl-4-biphenylacetate
(+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
(+-)-2-Fluoro-a-methyl-4-biphenylacetate
(+-)-2-Fluoro-a-methyl-4-biphenylacetic acid
(+-)-2-Fluoro-α-methyl-4-biphenylacetate
(+-)-2-Fluoro-α-methyl-4-biphenylacetic acid
(±)-2-fluoro-α-methyl-4-biphenylacetic acid
2-(2-Fluorobiphenyl-4-yl)propanoate
2-(2-Fluorobiphenyl-4-yl)propanoic acid
2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetate
2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
2-Fluoro-a-methyl-(1,1'-biphenyl)-4-acetate
2-Fluoro-a-methyl-(1,1'-biphenyl)-4-acetic acid
2-Fluoro-α-methyl-(1,1'-biphenyl)-4-acetate
2-Fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid
3-Fluoro-4-phenylhydratropate
3-Fluoro-4-phenylhydratropic acid
Abbott brand OF flurbiprofen
Adfeed
Allergan brand OF flurbiprofen sodium
Ansaid
Ansaid®|Froben®
Antadys
apo Flurbiprofen
apo-Flurbiprofen
Apotex brand OF flurbiprofen
BTS 18322
BTS-18322
Cantabria brand OF flurbiprofen
Cebutid
Crookes brand OF flurbiprofen
Dobrofen
FLP
Flubiprofen
Flugalin
FLURBIPROFEN
Flurbiprofen Axetil
Flurbiprofen pfizer brand
|
Flurbiprofen sodium
FLURBIPROFENE
Flurbiprofene [INN-French]
FLURBIPROFENO
Flurbiprofeno [INN-Spanish]
FLURBIPROFENUM
Flurbiprofenum [INN-Latin]
Fluriproben
Flurofen
Froben
Froben SR
Klosterfrau brand OF flurbiprofen
Knoll brand OF flurbiprofen
neo Artrol
novo Flurprofen
novo-Flurprofen
Novopharm brand OF flurbiprofen
Nu flurbiprofen
Nu pharm brand OF flurbiprofen
Nu-flurbiprofen
Nu-pharm brand OF flurbiprofen
Ocufen
Ocuflur
Pfizer brand OF flurbiprofen
Pharm allergan brand OF flurbiprofen sodium
Pharm-allergan brand OF flurbiprofen sodium
ratio Flurbiprofen
ratio-Flurbiprofen
Ratiopharm brand OF flurbiprofen
Recordati brand OF flurbiprofen
S-FLURBIPROFEN
Shire brand OF flurbiprofen
Sodium, flurbiprofen
Stayban
Strefen
TRANSACT
U-27182
Zepolas
|
|
32 |
|
Acarbose |
Approved, Investigational |
|
|
56180-94-0 |
441184 444254 |
Synonyms:
Acarbosa
Acarbose
Acarbosum
Bay g 5421
Bayer brand OF acarbose
BAY-G 5421
BAY-G 5421|BAY-G-5421|Glucobay®|Precose®
|
BAY-G-5421
Glucobay
Glucor
Glumida
Lasa brand OF acarbose
Prandase
Precose
|
|
33 |
|
Metformin |
Approved |
|
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
34 |
|
Remifentanil |
Approved |
|
|
132875-61-7 |
60815 |
Synonyms:
3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
GI 87084X
GI-87084B
IDS-NR-005
Remifentanil
|
Remifentanil hydrochloride
Remifentanil monohydrochloride
Remifentanilo
Remifentanyl
Ultiva
|
|
35 |
|
Diazepam |
Approved, Illicit, Investigational, Vet_approved |
|
|
439-14-5 |
3016 |
Synonyms:
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
Alboral
Aliseum
Alupram
ALUPRAM 10
ALUPRAM 2
ALUPRAM 5
Amiprol
An-Ding
Ansiolin
Ansiolisina
Apaurin
Apo-Diazepam
APOZEPAM
Armonil
Assival
ATENSINE
Atilen
Bensedin
Bialzepam
Calmocitene
Calmpose
Cercine
Ceregulart
DAP
Diacepan
Dialag
DIALAR
DIALAR FTE
Diapam
Diastat
DIASTAT ACUDIAL
Diastat®|LA-III|Valium®|WY-3467
Diazemuls
Diazemulus
Diazepam
DIAZEPAM CIV
DIAZEPAM INTENSOL
Diazepan
Diazetard
Dienpax
Dipam
Dipezona
DIZAC
Domalium
Duksen
Duxen
E-PAM
Eridan
Eurosan
Evacalm
Faustan
Faustan,
Freudal
Frustan
Gewacalm
Gihitan
Kabivitrum
Kiatrium
LA III
LA-III
Lamra
Lembrol
Levium
Liberetas
Mandrozep
Methyl diazepinone
Methyldiazepinone
Morosan
|
Neurolytril
Noan
Novazam
Novo-Dipam
NRL-1
NSC-169897
NSC-77518
Paceum
Pacitran
Paranten
Paxate
PAXEL
Plidan
Pms-Diazepam
Pro-Pam
Q-PAM
Q-Pam Relanium
Quetinil
Quiatril
Quievita
Relaminal
Relanium
Renborin
RO-52807
RO-5-2807
Ruhsitus
Saromet
SCRIPTOPAM
Sedapam
Sedipam
Seduksen
Seduxen
SERENACK
Serenamin
Serenzin
Servizepam
Setonil
Sibazon
Sibazone
SOLIS
Sonacon
Stesolid
Stesolin
TENSIUM
Tensopam
TRANIMUL
Tranqdyn
Tranquase
Tranquirit
Tranquo-Puren
Tranquo-Tablinen
Umbrium
Unisedil
Usempax Ap
Valaxona
VALCLAIR
Valeo
Valiquid
Valitran
Valium
VALRELEASE
Vatran
Velium
Vival
VIVOL
WY-3467
Zetran
Zipan
|
|
36 |
|
Benzocaine |
Approved, Investigational |
|
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
37 |
|
Tannic acid |
Approved |
|
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
38 |
|
Gastric inhibitory polypeptide |
Investigational |
|
|
100040-31-1 |
|
Synonyms:
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
|
|
|
39 |
|
Sitagliptin Phosphate |
|
|
|
654671-77-9 |
|
Synonyms:
JANUMET XR
JANUVIA
MK0431
MK-0431
ONO-5435
|
SITAGLIPTIN MONOPHOSPHATE ANHYDROUS
SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE HYDRATE
SITAGLIPTIN PHOSPHATE MONOHYDRATE
|
|
40 |
|
HIV Protease Inhibitors |
|
|
|
|
|
41 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
|
|
|
|
42 |
|
protease inhibitors |
|
|
|
|
|
Synonyms:
|
43 |
|
Pharmaceutical Solutions |
|
|
|
|
|
44 |
|
Cardiac Glycosides |
|
|
|
|
|
45 |
|
Glycoside Hydrolase Inhibitors |
|
|
|
|
|
46 |
|
Incretins |
|
|
|
|
|
47 |
|
bilirubin |
|
|
|
635-65-4 |
5280352 |
Synonyms:
(4Z,15Z)-Bilirubin ixa
(Z,Z)-Bilirubin ixa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoate
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
8,12-Bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione
BILIRUBIN
Bilirubin IX alpha
Bilirubin ixalpha
Bilirubin IX-alpha
Bilirubin(Z,Z)
Bilirubin-ixalpha
Cholerythrin
Hematoidin
NSC-26685
|
|
48 |
|
Liver Extracts |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 98)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis |
Completed |
NCT02823964 |
Phase 4 |
Liprotamase |
2 |
A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) |
Completed |
NCT01100606 |
Phase 4 |
EUR-1008 (APT-1008) |
3 |
A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) |
Completed |
NCT01131507 |
Phase 4 |
EUR-1008 (APT-1008) |
4 |
Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen |
Completed |
NCT01430234 |
Phase 4 |
Panzytrat 25.000 FIP-E units of Lipase |
5 |
An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) |
Completed |
NCT01327703 |
Phase 4 |
Panzytrat® 25,000;Kreon® 25,000 |
6 |
A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis |
Completed |
NCT03924947 |
Phase 4 |
Pancrelipase |
7 |
One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheresâ„¢ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year |
Completed |
NCT00535756 |
Phase 4 |
Creon;Placebo |
8 |
MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea |
Completed |
NCT00572975 |
Phase 4 |
|
9 |
A Phase 4 Study to Assess Symptoms of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon® (Pancrelipase) With an Alternate Source of Active Pharmaceutical Ingredient |
Recruiting |
NCT05069597 |
Phase 4 |
CREON |
10 |
Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects |
Terminated |
NCT03859869 |
Phase 4 |
Pancrelipase;Placebo |
11 |
Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency |
Terminated |
NCT00744250 |
Phase 4 |
Pancrelipase |
12 |
Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase |
Terminated |
NCT01865695 |
Phase 4 |
Creon |
13 |
Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy |
Withdrawn |
NCT01401387 |
Phase 4 |
|
14 |
A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer |
Withdrawn |
NCT04315311 |
Phase 4 |
CREON |
15 |
A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 |
Withdrawn |
NCT02009410 |
Phase 4 |
Creon;Creon 25000 matching Placebo |
16 |
A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
Unknown status |
NCT03051490 |
Phase 3 |
Liprotamase;porcine PERT |
17 |
Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency |
Unknown status |
NCT01012908 |
Phase 2, Phase 3 |
|
18 |
An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
Completed |
NCT00449904 |
Phase 3 |
Liprotamase |
19 |
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency |
Completed |
NCT00559364 |
Phase 3 |
Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole |
20 |
A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
Completed |
NCT02279498 |
Phase 3 |
Liprotamase;porcine (pig) PERT |
21 |
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy |
Completed |
NCT00414908 |
Phase 3 |
Pancrelipase delayed release capsule;Placebo Comparator |
22 |
A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI) |
Completed |
NCT00788593 |
Phase 3 |
Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose |
23 |
A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency |
Completed |
NCT00662675 |
Phase 3 |
Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21 |
24 |
A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
Completed |
NCT02734810 |
Phase 3 |
Liprotamase Powder for Oral Solution |
25 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
Completed |
NCT00449878 |
Phase 3 |
Liprotamase;Placebo |
26 |
An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency |
Completed |
NCT00981214 |
Phase 3 |
EUR-1008 (APT-1008) |
27 |
A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency |
Completed |
NCT00297167 |
Phase 3 |
EUR-1008 (APT-1008);Placebo |
28 |
A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis |
Completed |
NCT01641393 |
Phase 3 |
EUR-1008 25,000 Units;Kreon 25,000 Units |
29 |
A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy |
Completed |
NCT00400842 |
Phase 3 |
SA-001;Placebo |
30 |
A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF) |
Completed |
NCT00408317 |
Phase 3 |
Ultrase® MT20;Placebo |
31 |
A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis |
Completed |
NCT02137382 |
Phase 3 |
Creon®;Creon N |
32 |
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) |
Completed |
NCT00513682 |
Phase 3 |
Ultrase® MT20 |
33 |
A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy |
Completed |
NCT00401076 |
Phase 3 |
SA-001 |
34 |
A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension |
Completed |
NCT00705978 |
Phase 3 |
Pancreatin;Placebo |
35 |
A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis |
Completed |
NCT00690820 |
Phase 3 |
Pancrelipase Delayed Release;Placebo Comparator |
36 |
An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis |
Completed |
NCT00775528 |
Phase 3 |
Pancrelipase Delayed Release |
37 |
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis |
Completed |
NCT00432861 |
Phase 3 |
PANCRECARB® (pancrelipase);Placebo |
38 |
Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old |
Completed |
NCT00880100 |
Phase 3 |
Ultrase® MT12 |
39 |
An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis |
Completed |
NCT01747330 |
Phase 3 |
Pancreatin |
40 |
Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects |
Recruiting |
NCT03450772 |
Phase 3 |
Creon® 25000;Creon® 10000 |
41 |
Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency |
Not yet recruiting |
NCT04231279 |
Phase 3 |
synthetic human secretin |
42 |
An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy |
Terminated |
NCT00500084 |
Phase 3 |
Liprotamase |
43 |
A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis |
Completed |
NCT03746483 |
Phase 2 |
MS1819;Porcine PERT |
44 |
An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI). |
Completed |
NCT00559052 |
Phase 2 |
VIOKASE 16 |
45 |
OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules |
Completed |
NCT04375878 |
Phase 2 |
MS1819;Porcine PERT |
46 |
A Multicenter, Open-label Phase 2 Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs, to Investigate the Efficacy and Safety of This Combination for the Compensation of Severe Exocrine Pancreatic Insufficiency in CF Patients Not Fully Compensated With Only PPEs |
Completed |
NCT04302662 |
Phase 2 |
MS1819-SD |
47 |
A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLECâ„¢ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency |
Completed |
NCT00095732 |
Phase 2 |
Liprotamase;Placebo |
48 |
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis |
Completed |
NCT01710644 |
Phase 1, Phase 2 |
Burlulipase;Placebo (Caramel in sterile water) |
49 |
A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy |
Completed |
NCT03481803 |
Phase 2 |
MS1819-SD |
50 |
An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency |
Completed |
NCT00743483 |
Phase 2 |
rhBSSL |
|